Vectus Receives Supportive FDA Feedback Ahead Of VB0004 Patient Trial
VBS: $0.053 +0.00% · MC: $4M
Vectus Biosystems says FDA written feedback on its planned VB0004 study for idiopathic pulmonary fibrosis was supportive and provided practical guidance across manufacturing, nonclinical and clinical matters. The company will incorporate the responses into its Investigational New Drug package for a planned Phase Ib/IIa study in Australia; it says completing the package is now its focus.

Comments